Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06744647 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT06744647 · ClinicalTrials.gov record · last posted 2026-08-11

Phase 2 Study of ALXN2030 in Patients With Antibody-Mediated Rejection After Kidney Transplantation

Name: Phase 2 Study of ALXN2030 in Patients With Antibody-Mediated Rejection After Kidney Transplantation — clinical trial record (NCT06744647)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: CONCORD

StatusActive, Not Recruiting

PhasePhase 2

SponsorAlexion Pharmaceuticals, Inc.

Started2025-03-07

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

The primary objective of this study is to evaluate the efficacy of ALXN2030 compared with placebo on biopsy proven histologic resolution in participants with active or chronic active antibody-mediated rejection (AMR) at Week 52.

Protocol amendment history 2 changes detected by DataLookout

2026-08-12

Enrollment closed, study ongoing

2026-08-12

Trial sites reduced: 55 → 51 locations

Trial Details

NCT Number	NCT06744647
Lead Sponsor	Alexion Pharmaceuticals, Inc.
Conditions	Antibody-Mediated Rejection, Kidney Transplantation, Biopsy-proven Histologic Scores, AMR
Enrollment	47 participants
Start Date	2025-03-07
Primary Completion	2027-10-11 (estimated)
Study Completion	2028-11-07 (estimated)
Updated on ClinicalTrials.gov	2026-08-11